Skip to main content

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

Publication ,  Journal Article
Yao, JC; Phan, A; Hoff, PM; Chen, HX; Charnsangavej, C; Yeung, S-CJ; Hess, K; Ng, C; Abbruzzese, JL; Ajani, JA
Published in: J Clin Oncol
March 10, 2008

PURPOSE: Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alpha-2b was evaluated among patients with metastatic or unresectable carcinoid tumors. PATIENTS AND METHODS: Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatment with bevacizumab or PEG interferon alpha-2b. At disease progression (PD) or at the end of 18 weeks (whichever occurred earlier), patients received bevacizumab plus PEG interferon until progression. Functional computer tomography (CT) scans were performed to measure effect on tumor blood flow. RESULTS: In the bevacizumab arm, four patients (18%) achieved confirmed partial response (PR), 17 patients (77%) had stable disease (SD), and one patient (5%) had PD. In the PEG interferon arm, 15 patients (68%) had SD and six patients (27%) had PD. Progression-free survival (PFS) rates after 18 weeks of monotherapy were 95% in bevacizumab versus 68% on the PEG interferon arm. The overall median PFS for all 44 patients is 63 weeks. Compared with paired baseline measurements on functional CT scans, we observed a 49% (P < .01) and 28% (P < .01) decrease in tumor blood flow at day 2 and week 18 among patients treated with bevacizumab. No significant changes in tumor blood flow were observed following PEG interferon. PEG interferon alpha-2b treatment was associated with decrease in plasma basic fibroblast growth factor (bFGF; P = .04) and increase in plasma interleukin-18 (IL-18; P < .01). No significant changes in bFGF or IL-18 following treatment with bevacizumab were observed. CONCLUSION: Bevacizumab therapy resulted in objective responses, reduction of tumor blood flow, and longer PFS in patients with carcinoid than PEG interferon treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 10, 2008

Volume

26

Issue

8

Start / End Page

1316 / 1323

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Survival Rate
  • Recombinant Proteins
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Octreotide
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Interleukin-18
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S.-C., … Ajani, J. A. (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26(8), 1316–1323. https://doi.org/10.1200/JCO.2007.13.6374
Yao, James C., Alexandria Phan, Paulo M. Hoff, Helen X. Chen, Chusilp Charnsangavej, Sai-Ching J. Yeung, Kenneth Hess, Chaan Ng, James L. Abbruzzese, and Jaffer A. Ajani. “Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.J Clin Oncol 26, no. 8 (March 10, 2008): 1316–23. https://doi.org/10.1200/JCO.2007.13.6374.
Yao, James C., et al. “Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.J Clin Oncol, vol. 26, no. 8, Mar. 2008, pp. 1316–23. Pubmed, doi:10.1200/JCO.2007.13.6374.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung S-CJ, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10;26(8):1316–1323.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 10, 2008

Volume

26

Issue

8

Start / End Page

1316 / 1323

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Survival Rate
  • Recombinant Proteins
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Octreotide
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Interleukin-18